Elucidation of novel autoantibodies against axo-glial junctions in chronic inflammatory demyelinating radiculopolyneuropathy
| Project/Area Number |
24591265
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIMURA Satoshi 九州大学, 大学病院, 助教 (20596390)
MATSUSE Dai 九州大学, 大学病院, 助教 (70596395)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 神経免疫 / 自己抗体 / 慢性炎症性脱髄性多発根ニューロパチー / ランビエ絞輪 / 慢性炎症性多発根神経炎 / Neurofascin / 新規自己抗原 / 中枢末梢連合脱髄症 / ELISA / cell-based assay / 慢性炎症性脱髄性多発根神経炎 / ウエスタンブロット / セルベーストアッセイ |
|---|
| Outline of Final Research Achievements |
In this study, we clarified that 18% of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) were positive for antibodies against neurofascin 155 (NF155), which is cell-adhesion molecule and located around nodes of Ranvier. The anti-NF155 antibody-positive CIDP patients had significantly younger onset age, more frequent occurrence of distal acquired demyelinating symmetric phenotype and tremor, longer distal and F wave latencies, greater cerebrospinal fluid protein levels, and greater cervical root diameters than anti-NF155 antibody-negative CIDP patients. Marked symmetric hypertrophy of cervical and lumbosacral roots/plexuses was present in all the anti-NF155 antibody-positive CIDP patients examined by MRI neurography. A part of the anti-NF155 antibody-positive CIDP patients also had demyelination in the central nervous system, which suggested that this autoantibody could induce combined central and peripheral demyelination.
|
Report
(4 results)
Research Products
(18 results)
-
-
-
[Journal Article] Anti-neurofascin antibody in patients with combined central and peripheral demyelination2013
Author(s)
Nobutoshi Kawamura, Ryo Yamasaki, Tomomi Yonekawa, Takuya Matsushita, Susumu Kusunoki, Shigemi Nagayama, Yasuo Fukuda, Hidenori Ogata, Dai Matsuse, Hiroyuki Murai, Jun-ichi Kira
-
Journal Title
Neurology
Volume: 81
Issue: 8
Pages: 714-722
DOI
Related Report
Peer Reviewed
-
-
[Presentation] Prevalence and features of anti-neurofascin 155 antibody-positive CIDP2015
Author(s)
H Ogata, MD, R Yamasaki, MD, PhD, D Matsuse, MD, PhD, N Kawamura, MD, PhD, T Matsushita, MD, PhD, JI Kira, MD, PhD
Organizer
第56回 日本神経学会学術大会
Place of Presentation
新潟
Year and Date
2015-05-20
Related Report
-
[Presentation] Prevalence and characteristic features of anti-human neurofascin 155 antibody-associated chronic inflammatory demyelinating polyradiculoneuropathy2015
Author(s)
H Ogata, MD, R Yamasaki, MD, PhD, D Matsuse, MD, PhD, N Kawamura, MD, PhD, T Matsushita, MD, PhD, JI Kira, MD, PhD.
Organizer
The 67th American Academy of Neurology Annual Meeting
Place of Presentation
Washington, DC
Year and Date
2015-04-23
Related Report
-
-
[Presentation] Anti-Neurofascin Antibodies in the Inflammatory Demyelinating Diseases2014
Author(s)
H Ogata, MD, R Yamasaki, MD, PhD, D Matsuse, MD, PhD, N Kawamura, MD, PhD, T Matsushita, MD, PhD, JI Kira, MD, PhD.
Organizer
MSサマーカレッジ
Place of Presentation
福岡
Year and Date
2014-08-02
Related Report
-
-
-
-
-
[Presentation] Combined Central and Peripheral Demyelination: Diagnostic Value of Anti-Neurofascin Antibody and the First Nationwide Survey In Japan2013
Author(s)
Ogata H, Yamasaki R, Matsuse D, Kawamura N, Yonekawa T, Matsushita T, Imamura S, Kusunoki S, Nagayama S, Fukuda Y, Murai H, Kira JI
Organizer
the 6th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis
Place of Presentation
京都
Related Report
-
-
-
-
-
